Plasma sTNFR1 and IL8 for prognostic enrichment in sepsis trials: a prospective cohort study

[1]  J. Laffey,et al.  Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial. , 2018, The Lancet. Respiratory medicine.

[2]  Gilles Clermont,et al.  Precision medicine for all? Challenges and opportunities for a precision medicine approach to critical illness , 2017, Critical Care.

[3]  C. Robinson-Cohen,et al.  A Two‐Biomarker Model Predicts Mortality in the Critically Ill with Sepsis , 2017, American journal of respiratory and critical care medicine.

[4]  M. Singer,et al.  The intensive care medicine research agenda on septic shock , 2017, Intensive Care Medicine.

[5]  M. Shankar-Hari,et al.  The use of enrichment to reduce statistically indeterminate or negative trials in critical care , 2017, Anaesthesia.

[6]  C. Lindsell,et al.  An Enrichment Strategy For Sepsis Clinical Trials , 2016, Shock.

[7]  E. Dolgin.  BMS bets on targeting IL-8 to enhance cancer immunotherapies , 2016, Nature Biotechnology.

[8]  K. Famous,et al.  Acute Respiratory Distress Syndrome Subphenotypes Respond Differently to Randomized Fluid Management Strategy , 2016, American journal of respiratory and critical care medicine.

[9]  M. Mikkelsen,et al.  Neutropenic sepsis is associated with distinct clinical and biological characteristics: a cohort study of severe sepsis , 2016, Critical Care.

[10]  Derek C Angus,et al.  Toward Smarter Lumping and Smarter Splitting: Rethinking Strategies for Sepsis and Acute Respiratory Distress Syndrome Clinical Trial Design. , 2016, American journal of respiratory and critical care medicine.

[11]  Christopher W Seymour,et al.  Developing a New Definition and Assessing New Clinical Criteria for Septic Shock: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). , 2016, JAMA.

[12]  Ewout W Steyerberg,et al.  Net benefit approaches to the evaluation of prediction models, molecular markers, and diagnostic tests , 2016, British Medical Journal.

[13]  Adil Rafiq Rather,et al.  The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) , 2015 .

[14]  K. Gohil,et al.  Sepsis Treatment Options Are Often Lacking. , 2015, P & T : a peer-reviewed journal for formulary management.

[15]  S. Opal,et al.  Sepsis: a roadmap for future research. , 2015, The Lancet. Infectious diseases.

[16]  Benjamin R Saville,et al.  Decision curve analysis. , 2015, JAMA.

[17]  Cyrus Mehta,et al.  Biomarker driven population enrichment for adaptive oncology trials with time to event endpoints , 2014, Statistics in medicine.

[18]  H. Haller,et al.  Lung-Targeted RNA Interference Against Angiopoietin-2 Ameliorates Multiple Organ Dysfunction and Death in Sepsis , 2014, Critical care medicine.

[19]  Benjamin J. Raphael,et al.  Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin , 2014, Cell.

[20]  Kevin Delucchi,et al.  Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. , 2014, The Lancet. Respiratory medicine.

[21]  M. Quinlan.  A Randomized Trial of Protocol-based Care for Early Septic Shock , 2014 .

[22]  S. Opal,et al.  The Next Generation of Sepsis Clinical Trial Designs: What Is Next After the Demise of Recombinant Human Activated Protein C?* , 2014, Critical care medicine.

[23]  William Pao,et al.  Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. , 2014, JAMA.

[24]  Amber E Barnato,et al.  A randomized trial of protocol-based care for early septic shock. , 2014, The New England journal of medicine.

[25]  M. Antonelli,et al.  Albumin replacement in patients with severe sepsis or septic shock. , 2014, The New England journal of medicine.

[26]  B. Freidlin,et al.  Biomarker enrichment strategies: matching trial design to biomarker credentials , 2014, Nature Reviews Clinical Oncology.

[27]  C. Natanson,et al.  Antitumor Necrosis Factor Therapy Is Associated With Improved Survival in Clinical Sepsis Trials: A Meta-Analysis* , 2013, Critical care medicine.

[28]  Morgen M. Miller,et al.  Computing Adjusted Risk Ratios and Risk Differences in Stata , 2013 .

[29]  J. Vincent,et al.  Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. , 2013, JAMA.

[30]  M. Matthay,et al.  Plasma angiopoietin-2 predicts the onset of acute lung injury in critically ill patients. , 2013, American journal of respiratory and critical care medicine.

[31]  N. Shapiro,et al.  Angiopoietin-2 may contribute to multiple organ dysfunction and death in sepsis* , 2012, Critical care medicine.

[32]  S. Goodman,et al.  Beyond the Usual Prediction Accuracy Metrics: Reporting Results for Clinical Decision Making , 2012, Annals of Internal Medicine.

[33]  J. Utikal,et al.  Improved survival with MEK inhibition in BRAF-mutated melanoma. , 2012, The New England journal of medicine.

[34]  Dirk Schadendorf,et al.  Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group , 2012 .

[35]  D. Dumont,et al.  Effects of a synthetic PEG-ylated Tie-2 agonist peptide on endotoxemic lung injury and mortality. , 2011, American journal of physiology. Lung cellular and molecular physiology.

[36]  R. Temple,et al.  Enrichment of Clinical Study Populations , 2010, Clinical pharmacology and therapeutics.

[37]  Andrew J Vickers,et al.  Traditional statistical methods for evaluating prediction models are uninformative as to clinical value: towards a decision analytic framework. , 2010, Seminars in oncology.

[38]  B. Jeon,et al.  COMP-Ang1 ameliorates leukocyte adhesion and reinforces endothelial tight junctions during endotoxemia. , 2009, Biochemical and biophysical research communications.

[39]  A. Vickers.  Decision Analysis for the Evaluation of Diagnostic Tests, Prediction Models, and Molecular Markers , 2008, The American statistician.

[40]  P. Parren,et al.  IL-8 as Antibody Therapeutic Target in Inflammatory Diseases: Reduction of Clinical Activity in Palmoplantar Pustulosis1 , 2008, The Journal of Immunology.

[41]  Sangeeta Mehta,et al.  Vasopressin versus norepinephrine infusion in patients with septic shock. , 2008, The New England journal of medicine.

[42]  Steven B. Johnson,et al.  Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab′)2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels* , 2004, Critical care medicine.

[43]  C. Ryan,et al.  Objective estimates of the probability of death from burn injuries. , 1998, The New England journal of medicine.

[44]  W. Knaus,et al.  The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults. , 1991, Chest.

[45]  W. Knaus,et al.  APACHE II: a severity of disease classification system. , 1985 .

[46]  S. Opal,et al.  Mortality Benefit of Recombinant Human Interleukin-1 Receptor Antagonist for Sepsis Varies by Initial Interleukin-1 Receptor Antagonist Plasma Concentration* , 2018, Critical care medicine.

[47]  Arthur S Slutsky,et al.  Acute Respiratory Distress Syndrome The Berlin Definition , 2012 .

[48]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[49]  W. Youden,et al.  Index for rating diagnostic tests , 1950, Cancer.